Author + information
- Received June 16, 2015
- Revision received November 4, 2015
- Accepted December 1, 2015
- Published online March 1, 2016.
- Adam D. DeVore, MDa,b,∗ (, )
- Bradley G. Hammill, DrPHa,
- N. Chantelle Hardy, MPHa,
- Zubin J. Eapen, MD, MHSa,b,
- Eric D. Peterson, MD, MPHa,b and
- Adrian F. Hernandez, MD, MHSa,b
- aDuke Clinical Research Institute, Durham, North Carolina
- bDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina
- ↵∗Reprint requests and correspondence:
Dr. Adam D. DeVore, Duke Clinical Research Institute, P.O. Box 17969, Durham, North Carolina 27715.
Background In 2009, the Centers for Medicare & Medicaid Services (CMS) began publicly reporting 30-day hospital readmission rates for patients discharged with acute myocardial infarction (MI), heart failure (HF), or pneumonia.
Objectives This study assessed trends of 30-day readmission rates and post-discharge care since the implementation of CMS public reporting.
Methods We analyzed Medicare claims data from 2006 to 2012 for patients discharged after a hospitalization for MI, HF, or pneumonia. For each diagnosis, we estimated trends in 30-day all-cause readmissions and post-discharge care (emergency department visits and observation stays) by using hospitalization-level regression models. We modeled adjusted trends before and after the implementation of public reporting. To assess for a change in trend, we tested the difference between the slope before implementation and the slope after implementation.
Results We analyzed 37,829 hospitalizations for MI, 100,189 for HF, and 79,076 for pneumonia from >4,100 hospitals. When considering only recent trends (i.e., since 2009), we found improvements in adjusted readmission rates for MI (−2.3%), HF (−1.8%), and pneumonia (−2.0%), but when comparing the trend before public reporting with the trend after reporting, there was no difference for MI (p = 0.72), HF (p = 0.19), or pneumonia (p = 0.21). There were no changes in trends for 30-day post-discharge care for MI or pneumonia; however, the trend decreased for HF emergency department visits from 2.3% to −0.8% (p = 0.007) and for observation stays from 15.1% to 4.1% (p = 0.04).
Conclusions The release of the CMS public reporting of hospital readmission rates was not associated with any measurable change in 30-day readmission trends for MI, HF, or pneumonia, but it was associated with less hospital-based acute care for HF.
This project was supported in part by grant number U19HS021092 from the Agency for Healthcare Research and Quality (AHRQ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the AHRQ. Dr. Eapen has membership on the advisory boards of Novartis, Cytokinetics, and Amgen; is a consultant for Amgen and SHL Telemedicine; and has received an honorarium from Janssen. Dr. Peterson has received grant support from the American College of Cardiology, American Heart Association, and Janssen; and has been a consultant for Bayer, Boehringer Ingelheim, Merck, Valeant, Sanofi, AstraZeneca, Janssen, Regeneron, and Genentech. Dr. Hernandez has received research funding from Amgen, Inc., AstraZeneca, Bayer Corporation US, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., and Portola Pharmaceutical (all significant); has received personal income for consulting or other services (including CME) from Bayer Corporation US; and has received personal income for consulting or other non-CME services from Amgen, Inc., AstraZeneca, Bayer Corporation US, Eli Lilly & Co., Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Merck & Co., Novartis Pharmaceutical Co., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Pfizer, Pluristem Therapeutics, Inc., Sensible, and Myocardia. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received June 16, 2015.
- Revision received November 4, 2015.
- Accepted December 1, 2015.
- American College of Cardiology Foundation